• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Adaferin Gel
    / Rafa

    Active Ingredient
    Adapalene 0.1%

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    30 gr

    not in the basket chart 34128 1449

    Related information


    Adaferin Gel should be applied to the acne affected areas once a day before retiring and after washing. A thin film of gel should be applied, with the fingertips, avoiding the eyes and lips.Ensure that the affected areas are dry before application. Since it is customary to alternate therapies in the treatment of acne, it is recommended that the physician assess the continued improvement of the patient after three months of treatment with Adaferin  Gel. With patients for whom it is necessary to reduce the frequency of application or to temporarily discontinue treatment, frequency of application may be restored or therapy resumed once it is judged that the patient can again tolerate the treatment. If patients use cosmetics, these should be non-comedogenic and non-astringent.
    Paediatric population: The safety and effectiveness of Adaferin  Gel have not been studied in children below 12 years of age. Adaferin gel should not be used in patients with severe acne.


    Acne vulgaris.


    Hypersensitivity to the active substance or to any of the excipients listed.

    Special Precautions

    If a reaction suggesting sensitivity or severe irritation occurs, use of the medication should be discontinued. If the degree of local irritation warrants, patients should be directed to use the medication less frequently, to discontinue use temporarily, or to discontinue use altogether. Adaferin  Gel should not come into contact with the eyes, mouth, nostrils or mucous membranes. If product enters the eye, wash immediately with warm water. The product should not be applied to either broken (cut and abrasions) or eczematous skin, nor should it be used in patients with severe acne involving large areas of the body. The excipient propylene glycol (E1520) may cause skin irritation and methyl parahydroxybenzoate (E218) may cause allergic reactions which can possibly be delayed.

    Side Effects

    Using more than the recommended amount of Differin Gel may result in very red and sore skin.
    For full details see prescribing information.

    Drug interactions

    There are no known interactions with other medications which might be used cutaneously and concurrently with Adaferin  Gel, however, other retinoids or drugs with a similar mode of action should not be used concurrently with adapalene. Adapalene is essentially stable to oxygen and light and is chemically non-reactive. Whilst extensive studies in animals and man have shown neither phototoxic nor photoallergic potential for adapalene, the safety of using adapalene during repeated exposure to sunlight or UV irradiation has not been established in either animals or man. Exposure to excessive sunlight or UV irradiation should be avoided. Absorption of adapalene through human skin is low and therefore interaction with systemic medications is unlikely. There is no evidence that the efficacy of oral drugs such as contraceptives and antibiotics is influenced by the cutaneous use of Adaferin  Gel. Adaferin  Gel has a potential for mild local irritation, and therefore it is possible that concomitant use of peeling agents, abrasive cleansers, strong drying agents, astringents or irritant products (aromatic and alcoholic agents) may produce additive irritant effects. However, cutaneous antiacne treatment (eg erythromycin up to 4%) or clindamycin phosphate (1% as the base) solutions or benzoyl peroxide water based gels up to 10% may be used in the morning when Adaferin  Gel is used at night as there is no mutual degradation or cumulative irritation.

    Pregnancy and Lactation

    Pregnancy: Animal studies by the oral route have shown reproductive toxicity at high systemic exposure (see section 5.3). Clinical experience with locally applied adapalene in pregnancy is limited but the few available data do not indicate harmful effects on pregnancy or on the health of the foetus exposed in early pregnancy. Due to the limited available data and because a very weak cutaneous passage of adapalene is possible, Adaferin  should not be used during pregnancy. In case of unexpected pregnancy, treatment should be discontinued.
    Breast-feeding: No study on animal or human milk transfer was conducted after cutaneous application of Adaferin. No effects on the suckling child are anticipated since the systemic exposure of the breast-feeding woman to Adaferin  is negligible. Adaferin  can be used during breastfeeding. To avoid contact exposure of the infant, application of Adaferin  to the chest should be avoided when used during breast-feeding.


    Adaferin Gel is not to be taken orally and is for cutaneous use only. If the medication is applied excessively, no more rapid or better results will be obtained and marked redness, peeling or discomfort may occur. The acute oral dose of Adaferin  Gel required to produce toxic effects in mice is greater that 10 mg/kg. Nevertheless, unless the amount accidentally ingested is small, an appropriate method of gastric emptying should be considered.